China Vaccines Market Overview, 2028

China's vaccine market has been growing rapidly in recent years, driven by increasing healthcare spending, a growing middle class, and the government's focus on expanding vaccination programs. China has a robust domestic vaccine production industry. It produces a wide range of vaccines, including those for hepatitis, influenza, polio, and more. This self-sufficiency has allowed the country to respond quickly to outbreaks and pandemics. China has engaged in vaccine diplomacy by supplying vaccines to countries around the world, especially developing nations. This approach has allowed China to expand its global influence and strengthen diplomatic ties. The China vaccine market stands as a towering pillar within the global pharmaceutical landscape, characterised by rapid growth, pivotal contributions to the global fight against the COVID-19 pandemic, and a burgeoning export industry. With a robust domestic vaccine production sector, China has achieved self-sufficiency in vaccine manufacturing, spanning a wide spectrum of preventable diseases. Beyond its borders, the country has engaged in vaccine diplomacy, distributing its vaccines worldwide, strengthening international alliances, and solidifying its position as a global healthcare influencer. However, this flourishing market is not without its challenges, including the need to navigate regulatory reforms, address vaccine safety concerns, and adapt to evolving global health dynamics. As China continues to innovate, collaborate on international platforms, and expand its vaccination programmes, its role in shaping the future of vaccines on a global scale becomes increasingly prominent. Annually in China, more than 698 million vaccine doses are produced; China is one of the largest producers of vaccines. As a result, China has drawn significant attention to the vaccine industry, which plays a representative role. In addition, it is a closed market with a solid local vaccine industry, access to which is challenging for Western players. According to the research report "China Vaccines Market Overview, 2028," published by Bonafide Research, the China Vaccines Market was valued at more than USD 6 Billion in 2022. The Chinese government has implemented extensive vaccination programmes for both children and adults, covering a wide range of diseases. These programmes are a primary driver of vaccine demand as they ensure broad access to vaccines throughout the country. China's large and densely populated cities create a significant demand for vaccines. The high population density can facilitate the rapid spread of infectious diseases, making vaccination a crucial preventive measure. Increasing awareness of public health and disease prevention among the Chinese population has led to a higher demand for vaccines. Concerns about the spread of infectious diseases and a desire for improved healthcare have contributed to this trend. Chinese travellers and expatriates often require vaccines to protect themselves from diseases prevalent in other countries. The growth of international travel has increased the demand for travel-related vaccines. The development of healthcare infrastructure, including clinics, hospitals, and vaccination centres, has made vaccines more accessible to the population. Improved infrastructure encourages people to get vaccinated. Outbreaks of vaccine-preventable diseases, such as measles or mumps, can trigger a surge in vaccine demand as people seek protection. China's investment in vaccine research and development has led to the creation of new and improved vaccines, further stimulating demand for these advanced products. China's role in supplying vaccines to other countries as part of its vaccine diplomacy efforts can also influence domestic vaccine demand, as it showcases the efficacy and safety of Chinese vaccines.

According to the report, the technology is segmented into conjugate vaccines, inactivated and subunit vaccines, live-attenuated vaccines, recombinant vaccines, and toxoid vaccines. In China, the recombinant vaccine market is growing. China has made significant strides in biotechnology and genetic engineering, which are essential for the development of recombinant vaccines. These advancements enable researchers and pharmaceutical companies to create vaccines using genetic material and recombinant DNA technology, leading to the production of safer and more effective vaccines. China has established biotechnology hubs and research centres dedicated to vaccine development. These hubs foster collaboration between academia and industry and facilitate the exchange of knowledge and expertise, further accelerating technological advancements. Growing awareness of the benefits of recombinant vaccines and increasing public and government demand for safer and more effective vaccines drive investment and technological growth in this sector. China's efforts to supply vaccines to other countries as part of its vaccine diplomacy strategy have also spurred investment in recombinant vaccine technology. The global demand for high-quality vaccines has incentivized Chinese companies to develop and manufacture these products. Based on the end user segment, which includes paediatric vaccines and adult vaccines, the adult vaccine market in China is growing. China's population is ageing rapidly, with a growing proportion of elderly individuals. Older adults are more susceptible to certain vaccine-preventable diseases, such as influenza, pneumonia, and shingles. To protect this demographic group, there is a rising demand for vaccines tailored to adults. There is a growing awareness of the importance of preventive healthcare among Chinese adults. Government health campaigns and public education efforts have emphasised the role of vaccines in maintaining health and preventing diseases, contributing to increased demand. Certain occupations, such as healthcare workers and those in close contact with animals, may require specific vaccines to protect against occupational hazards. These requirements drive demand for adult vaccines in occupational settings. Expanding health insurance coverage in China has made vaccines more affordable and accessible for adults, further driving demand for preventive healthcare measures. Increased confidence in the safety and efficacy of vaccines among the Chinese population has contributed to greater acceptance of adult vaccinations. Based on the route of administration, they are segmented into intramuscular and subcutaneous administration, oral administration, and others. In a country where the Oral Administration is growing, China, like many other countries, has historically used oral polio vaccines (OPV) as part of global efforts to eradicate polio. These campaigns involve the oral administration of the vaccine, making it an important method for reaching a large population. Some diseases, such as rotavirus, enter the body through the gastrointestinal tract. Oral vaccines can stimulate mucosal immunity in addition to systemic immunity, which can be more effective in preventing diseases that affect the mucous membranes. Oral vaccines are suitable for mass vaccination campaigns targeting specific diseases or populations, which can be an effective strategy for disease control and prevention in a populous country like China. Some oral vaccines are more stable at higher temperatures compared to their injectable counterparts. This can be advantageous in regions with diverse climates and varying access to reliable refrigeration. According to the report, types are segmented into multivalent vaccines and monovalent vaccines, among them. Multivalent vaccines lead the market. Multivalent vaccines combine protection against multiple diseases into a single vaccine, reducing the number of shots needed. This simplification is particularly advantageous for children who require numerous vaccinations in their early years, making it easier for parents and healthcare providers to adhere to the recommended vaccination schedule. Combination vaccines are more efficient in terms of healthcare resources and logistics. They reduce the number of healthcare visits, the need for multiple syringes, and the storage space required for vaccines.

Make this report your own

Have queries/questions regarding a report?

Take advantage of intelligence tailored to your business objective

Ask an Expert

Manmayi Raval

Research Consultant

In terms of disease types, they include the rotavirus, pneumococcal diseases, cancer, influenza, diphtheria, pertussis, and tetanus, the human papilloma virus (HPV), hepatitis, shingles, meningococcal diseases, varicella, mumps, and others. In China, the rotavirus has the highest market share. The rotavirus is a highly contagious virus that can cause severe diarrhoea, leading to dehydration, hospitalisations, and even death, primarily in young children. The disease burden of rotavirus gastroenteritis is significant in China, making it a public health concern. The Chinese government recognises the importance of preventing rotavirus-related illnesses and has made rotavirus vaccination a public health priority. This prioritisation can lead to the inclusion of rotavirus vaccines in national immunisation programs. China has a well-established routine childhood immunisation programmeme, and rotavirus vaccines may be integrated into this ram. The inclusion of rotavirus vaccines in the routine schedule ensures that a large proportion of infants receive the vaccine. Severe rotavirus infections can strain healthcare resources and lead to increased hospitalizations. Preventing these illnesses through vaccination can alleviate the burden on the healthcare system. Distribution channels include hospital pharmacy, retail pharmacy, institutional sales, and others in China. Retail pharmacy is a growing market, and retail pharmacies are easily accessible to the general population, offering a convenient location for individuals to receive vaccines without the need for a doctor's appointment or a visit to a healthcare facility. This convenience encourages more people to get vaccinated. China has been investing in expanding its healthcare infrastructure, including the development of retail pharmacy chains. This growth in infrastructure means that more people have access to retail pharmacies where vaccines can be administered. Pharmacists in retail pharmacies are increasingly qualified and authorised to administer vaccines. Their expertise and accessibility make retail pharmacies a trusted destination for vaccination services. Retail pharmacies in China offer a wider range of vaccines, including routine childhood vaccines, adult vaccines, and travel vaccines. This diversification of vaccine offerings makes retail pharmacies a one-stop shop for vaccination needs. Considered in this report: • Geography: China • Historic year: 2017 • Base year: 2022 • Estimated year: 2023 • Forecast year: 2028

Don’t pay for what you don’t need. Save 30%

Customise your report by selecting specific countries or regions

Specify Scope Now

Aspects covered in this report: • China Vaccines market Outlook with its value and forecast along with its segments • Various drivers and challenges • On-going trends and developments • Top profiled companies • Strategic recommendation By Technology • Conjugate vaccines • Inactivated & Subunit vaccines • Live Attenuated vaccines • Recombinant vaccines • Toxoid vaccines • Viral vector vaccines • Others By Route of Administration • Intramuscular and Subcutaneous Administration • Oral Administration • Others By Disease • Rotavirus • Pneumococcal diseases • Cancer • Influenza • Diphtheria, Pertussis, and Tetanus (DTP) • Human Papilloma Virus (HPV) • Hepatitis • Shingles • Meningococcal diseases • Varicella (Chicken Pox) • Mumps • Others By Type • Multivalent vaccines • Monovalent vaccines By End-User Type • Paediatrics • Adults By Distribution Channel • Hospital Pharmacy • Retail Pharmacy • Online Pharmacy • Others The approach of the report: This report consists of a combined approach of primary as well as secondary research. Initially, secondary research was used to get an understanding of the market and list out the companies that are present in the market. The secondary research consists of third-party sources such as press releases, and annual reports of companies, analyzing the government-generated reports and databases. After gathering the data from secondary sources primary research was conducted by making telephonic interviews with the leading players about how the market is functioning and then conducting trade calls with dealers and distributors of the market. Post this we have started doing primary calls to consumers by equally segmenting consumers into regional aspects, tier aspects, age groups, and gender. Once we have primary data with us we started verifying the details obtained from secondary sources. Intended audience: This report can be useful to industry consultants, manufacturers, suppliers, associations & organizations related to the Drone industry, government bodies, and other stakeholders to align their market-centric strategies. In addition to marketing & presentations, it will also increase competitive knowledge about the industry.